JUL 04, 2018 2:11 AM PDT

First Drug Approved for The Treatment of Hyperhidrosis

WRITTEN BY: Nouran Amin

Hyperhidrosis is a chronic skin condition that results in the increased production of sweat than needed. A certain amount of sweat is normally produced to regulate body temperature, an excess of sweat becomes unnecessary.

Now, the U.S. Food and Drug Administration (FDA) has approved the first drug developed to reduce excessive sweating. The drug will particularly be effective in one type of hyperhidrosis caused under the armpit, better known as primary axillary hyperhidrosis.

According to the drug manufacturing California-based pharmaceutical company, Dermira Inc, the drug which is now known as Qbrexza and will be available in pharmacies in October 2018.

Affected individuals prescribed Qbrexza will receive it as a drug packed inside a cloth. They will be able to use it to wipe over their skin every day to block the sweat glands from activating and thus no sweat will be released from the treated area.

Roughly 15 million Americans experience some form of excessive sweating, with more than 10 million individuals experiencing excessive underarm perspiration.

Excessive sweating is often associated with social embarrassment and emotional burdens to affected individuals. Such distress due to this skin condition has inspired dermatologists to seek effective treatment options.

“From the start, our goal was to develop an approach that went beyond masking a person’s excessive underarm sweating and instead focused on treating the condition in a clinically meaningful way," says Derira Chairman Tom Wiggans.

The FDA approval of Qbrexza was based on two clinical trials.

Most frequent noted side effects of Qbrexza include dry mouth, dilated pupils, sore throat, headache, urinary hesitation, blurred vision, dry nose, dry eyes, dry skin and constipation.

About the Author
BS/MS
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
APR 19, 2022
Drug Discovery & Development
Repurposing an Alcoholism Drug to Treat Anxiety
APR 19, 2022
Repurposing an Alcoholism Drug to Treat Anxiety
Anxiety is the most common mental illness in the U.S. According to the National Institutes of Health, nearly a third of ...
APR 20, 2022
Immunology
Rare Soil Microbe Shows Promise as New Antibiotic
APR 20, 2022
Rare Soil Microbe Shows Promise as New Antibiotic
  Antibiotic resistance has increased the demand for new antibiotic treatments. Now, researchers have found that a ...
APR 21, 2022
Health & Medicine
Inhibiting a Key Signaling Pathway in Immune Cells Slows Alzheimer's Progression
APR 21, 2022
Inhibiting a Key Signaling Pathway in Immune Cells Slows Alzheimer's Progression
Weill Cornell Medicine researchers recently discovered that inhibiting a key signaling pathway in brain cells can lessen ...
APR 21, 2022
Drug Discovery & Development
No Link Between Antidepressants and Improved Quality of Life
APR 21, 2022
No Link Between Antidepressants and Improved Quality of Life
Those who use antidepressant medications have a similar health-related quality of life to people who are depressed and w ...
APR 28, 2022
Health & Medicine
Antidepressants Not Associated Improved Quality of Life
APR 28, 2022
Antidepressants Not Associated Improved Quality of Life
According to a recently published study in PLoS, antidepressants do not improve health-related quality of life (HRQoL) o ...
MAY 22, 2022
Drug Discovery & Development
Gout Medication Helps Hospitalized People with Heart Failure
MAY 22, 2022
Gout Medication Helps Hospitalized People with Heart Failure
A research team at the University of Virginia Hospital System found that a regularly-used medication for gout, called co ...
Loading Comments...